Short Communications

Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy

David A. Sola-Del Valle1,†, Sumit Mohan1,†, Jen-Tse Cheng1, Neal A. Paragas1, Meghan E. Sise1, Vivette D’Agati2 and Jonathan Barasch1

1Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, NY, USA and 2Department of Pathology, Columbia University Medical Center, New York, NY, USA

Correspondence and offprint requests to: Sumit Mohan; E-mail: sm2206@columbia.edu

†Both authors contributed equally to this work.

Abstract

Background. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) is expressed by kidney tubules that are acutely damaged, but few studies have investigated the association of neutrophil gelatinase-associated lipocalin (NGAL) with different forms of chronic kidney disease (CKD). HIV-associated nephropathy (HIVAN) is a progressive form of CKD characterized by collapsing focal segmental glomerulosclerosis and microcystic tubular dilation that typically leads to end-stage renal disease (ESRD).

Methods. Previously, we reported that microcystic tubular dilatations specifically expressed NGAL RNA, implying that the detection of uNGAL protein could mark advanced HIVAN. To test this idea, we performed a comparative study of diverse proteinuric glomerulopathies in 25 patients who were HIV positive.

Results. Eighteen patients had HIVAN and seven had other glomerulopathies (four membranoproliferative glomerulonephritis, one membranous glomerulonephritis, one amyloid and one malarial GN). HIVAN and non-HIVAN patients did not differ with respect to age, ethnicity, serum creatinine, estimated GFR, proteinuria or the prevalence of hypocomplementemia (6 versus 29%, P = 0.18), but HIVAN patients were less likely to have HCV infections. HIVAN patients expressed 4-fold higher levels of uNGAL than the patients with other glomerulopathies [387 ± 338 versus 94 ± 101 μg/g urine creatinine (uCr), P = 0.02]. A cutpoint of 121.5 μg uNGAL/g uCr demonstrated 94% sensitivity and 71% specificity for the diagnosis of HIVAN, with an area under the receiver operator characteristic curve of 0.88.

Conclusion. In summary, while HIVAN disease is currently diagnosed only by kidney biopsy, uNGAL can distinguish HIVAN from other proteinuric glomerulopathies in the HIV-infected patient, likely because of its specific expression from characteristic microcysts.

Keywords: biomarker; HIV-associated nephropathy; progressive chronic kidney disease; tubular injury; urinary neutrophil gelatinase-associated lipocalin

Introduction

HIV-associated nephropathy (HIVAN) remains the most common and aggressive cause of kidney disease among HIV-positive patients, particularly in those of African descent [1–4]. HIVAN is characterized by heavy proteinuria and a rapid loss of kidney function and is the third leading cause of end-stage renal disease (ESRD) among black patients between the ages of 20 and 64 years [5,6]. Renal biopsy is currently the only method of diagnosing HIVAN, yet renal biopsy is impractical in many countries where HIVAN is prevalent, and the procedure is not without risks [1,7–13]. Here, we investigate a potential noninvasive surrogate marker of HIVAN in proteinuric HIV-infected patients.

Urinary neutrophil gelatinase-associated lipocalin (uNGAL) is secreted from the tubular portion of the nephron as a full-length protein just 3 h after the onset of an acute stimulus that damages the nephron [14,15]. Subsequently, uNGAL resolves over a number of days when the stimulus is withdrawn [14,16]. Hence, while the association of uNGAL and acute damage is clear, it has not been appreciated whether uNGAL is also expressed by the chronically damaged kidney. In fact, we found that uNGAL was expressed only at low levels in most types of chronic kidney disease (CKD) with the notable exception of HIVAN where tubular microcysts expressed the protein [16–22]. These data implied that among different forms of CKD, uNGAL may be a unique marker of HIVAN.

Methodology

Twenty-five HIV-positive patients who underwent renal biopsy and donated urine at the time of the biopsy were compared with age-, race- and gender-
matched HIV-negative control subjects. Renal biopsies were processed at CUMC for light microscopy, immunofluorescence and electron microscopy. Urine samples were stored at −80°C until uNGAL (10 μL) was quantified by immunoblots with non-reducing 4%–15% gradient polyacrylamide gels (Bio-Rad Laboratories) using standards (0.3–3 ng) of human recombinant neutrophil gelatinase-associated lipocalin (NGAL) protein (Figure 1) [16]. Immunoblots were used to detect and quantify the monomeric form of NGAL, which is necessary since some CKD patients express complexes of NGAL linked to other proteins, whereas only the monomeric form has been validated epidemiologically in association with renal disease (Nickolas and Barasch, unpublished data). Urinary liver fatty acid-binding protein (uL-FABP) was measured using a sandwich-type ELISA kit (CMIC Co., Ltd). Urinary N-acetyl-β-d-glucosaminidase (uNAG) was measured using a colorimetric assay kit (Roche Applied Sciences). Investigators were blinded while performing the assays.

The data are represented both as a concentration and as the absolute values corrected for urinary creatinine. Both measurements are reported for the following reason: a normalized ratio can be misleading in cases of acute renal failure because of rapid decline in the creatinine excretion which would amplify the urinary biomarker signal [23]. However, in patients with CKD, the rate of change of GFR is much slower such that ESRD is reached. Hence, we report both the absolute biomarker level nor-

![hNGAL Standards](#)  
**Fig. 1.** Immunoblots showing monomeric uNGAL expression in HIV patients. Three HIVAN patients and three HIV-positive patients with other glomerulopathies' representative of our cohort are shown. Human recombinant NGAL standards (ng) are shown.

### Results

Our cohort consisted of 18 patients with HIVAN, 4 patients with membranoproliferative glomerulonephritis, 1 with membranous glomerulopathy, 1 with malaria glomerulonephritis and 1 with renal AA amyloidosis. Baseline characteristics of our cohort are presented in Table 1.

Patients with HIVAN and non-HIVAN glomerulopathies were comparable with respect to age, renal function [BUN, serum creatinine (sCr) and estimated GFR (eGFR)], nutritional status (serum albumin and cholesterol), proteinuria and complement levels. In addition, CD4 counts, HCV co-infection and use of highly active antiretroviral therapy did not differ between the groups (Table 1).

Compared to HIV-positive patients with non-HIVAN glomerulopathies, patients with HIVAN had significantly elevated levels of uNGAL as well as uL-FABP, a second indicator of tubular injury. However, there was no difference in uNAG levels between the two groups of patients (Table 1). We also found significantly higher levels of uNGAL and uL-FABP in HIVAN patients compared to our HIV-negative controls.

A significant correlation between uNGAL (μg/g) and uL-FABP (μg/g) but not between these two biomarkers and uNGAL (μg/g) was present in our cohort of 25 HIV-positive patients (see table 2). Neither uNGAL nor uL-FABP correlated with sCr, eGFR (MDRD) BUN or proteinuria (see table 2). uNGAL levels were not influenced by the use of HAART (not on HAART 246 ± 285 versus on HAART 407 ± 309, P = 0.45), hypocomplementemia (108 ± 98 versus 297 ± 322, P = 0.28) or HCV infection (159 ± 128 versus 236 ± 312, P = 0.65) and did not show any correlation with CD4 counts (−0.004, P = 0.99). Among HIVAN patients, the percentage of collapsed glomeruli correlated with the sCr and 24-h proteinuria (r = 0.49, P = 0.01; r = 0.48, P = 0.03, respectively) but not with either uNGAL (r = 0.29, P = 0.15) or with uL-FABP (r = 0.1, P = 0.64).

The receiver operator characteristic (ROC) curve for uNGAL (μg/g of uCr) had an area under the curve (AUC)
of 0.88 (Figure 2). The concentration of uNGAL with the highest Youden index was 121.5 μg/g uCr, which had a sensitivity of 94% and specificity of 71% (Table 3) for the detection of HIVAN. At a cutpoint of 121.5 μg/g uCr, 88% of cases were correctly classified with a positive likelihood ratio of 3.3 and a positive predictive value of 89%. The ROC curve for uL-FABP (μg/g uCr) had an AUC of 0.80, and the threshold of 116 μg/g uCr had similar sensitivity and specificity ($\chi^2 = 1.74$, $P = 0.2$; Figure 2 and Table 3).

By contrast, the discriminatory ability to distinguish HIVAN from other glomerulopathies was significantly worse for uNAG and the more traditional markers such as sCr and proteinuria (Figure 2 and Table 4).

**Table 2.** Correlation coefficients between various renal biomarkers

<table>
<thead>
<tr>
<th></th>
<th>uNGAL</th>
<th>uL-FABP</th>
</tr>
</thead>
<tbody>
<tr>
<td>uL-FABP</td>
<td>0.52 (0.007)</td>
<td>-</td>
</tr>
<tr>
<td>uNAG</td>
<td>0.34 (0.1)</td>
<td>0.17 (0.42)</td>
</tr>
<tr>
<td>Serum creatinine</td>
<td>0.31 (0.12)</td>
<td>0.09 (0.67)</td>
</tr>
<tr>
<td>Estimated GFR (MDRD)</td>
<td>0.13 (0.60)</td>
<td>0.24 (0.34)</td>
</tr>
<tr>
<td>BUN</td>
<td>−0.02 (0.92)</td>
<td>0.14 (0.56)</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>0.23 (0.33)</td>
<td>−0.08 (0.75)</td>
</tr>
</tbody>
</table>

*Data reported as correlation coefficient (P-value).*

**Fig. 2.** ROC curves demonstrating the utility of uNGAL to diagnose HIVAN among HIV-positive patients with proteinuria compared to other markers.

**Table 3.** Urine NGAL and urine L-FABP test ROC curve characteristics

<table>
<thead>
<tr>
<th>uNGAL (μg/g)</th>
<th>uL-FABP (μg/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>73.8</td>
<td>55.8</td>
</tr>
<tr>
<td>121.5</td>
<td>116.2</td>
</tr>
<tr>
<td>144.4</td>
<td>312.5</td>
</tr>
<tr>
<td>182</td>
<td>589.8</td>
</tr>
</tbody>
</table>

| Sensitivity (%) | 100 | 94.4 | 77.8 | 66.7 | 50 |
| Specificity (%) | 57.1 | 71.4 | 85.7 | 85.7 | 86 |
| Youden index | 0.57 | 0.66 | 0.63 | 0.52 | 0.44 |
| Correctly classified (%) | 88 | 88 | 80 | 72 | 60 |
| Positive likelihood ratio | 2.3 | 3.3 | 5.4 | 4.7 | 3.6 |
| Negative likelihood ratio | NA | 0.08 | 0.3 | 0.4 | 0.6 |
| Positive predictive value (%) | 86 | 89 | 93 | 92 | 90 |
| Negative predictive value (%) | 100 | 82 | 60 | 50 | 40 |

*$^a$NA, not applicable.
relate with GFR. In summary, it appears that two markers of tubular damage more specifically detect disease progression than markers of glomerular filtration, but we do not have an explanation for the failure of uNAG, which is released following structural damage to the tubular cells, including subclinical injury related to tenofovir, to predict HIVAN [28,31].

We conclude that HIVAN can be identified by two genes expressed in response to tubular rather than glomerular damage. uNGAL provides the best noninvasive clinical marker of HIVAN. Because our study was limited by the absence of long-term follow-up as well as the limited number of HIV-positive patients with non-HIVAN diagnoses, our data currently suggest two hypotheses for future testing: that uNGAL will be useful in parts of the world where HIVAN is prevalent but renal biopsy is not practical, and second that uNGAL predicts progression in cystic-HIV CKD but not other forms of CKD.

Acknowledgements. Funding. Supported by grants from the US National Institute of Diabetes and Digestive and Kidney Diseases (DK-55388 and DK-58872) and the March of Dimes for Birth Defects. Additional funding to J.B. was provided by the Glomerular Center of Columbia University. D.A.S was funded by the Doris Duke Charitable Foundation. Columbia has licensed NGAL for use in kidney disease to Abbott Labs and to Biosite/Alere Corporation.

Conflict of interest statement. None declared.

References

Received for publication: 11.11.11; Accepted in revised form: 12.4.11